Overview

Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer

Status:
Terminated
Trial end date:
2020-03-17
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well olaparib, cediranib maleate, and standard chemotherapy work in treating patients with small cell lung cancer. Drugs used in chemotherapy, such as carboplatin, cisplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Olaparib and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib, cediranib maleate, and standard chemotherapy may work better in treating patients with small cell lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Carboplatin
Cediranib
Cisplatin
Etoposide
Etoposide phosphate
Maleic acid
Olaparib
Podophyllotoxin
Poly(ADP-ribose) Polymerase Inhibitors
Succinylcholine